Oncology | New Developments | UNITED KINGDOM

Tiziana Life Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody

Lead Product(s): Foralumab,CAR-T Therapy

Therapeutic Area: Oncology Product Name: TZLS-401

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 16, 2020

Details:

Tiziana has submitted a patent application on potential use of Foralumab, a fully human anti-CD3 monoclonal antibody (mAb), to improve success of CAR-T therapy for cancer and other human diseases.

Microbiotica

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Microbiotica, Cancer Research UK and Cambridge University Hospitals Collaborate in Landmark Cancer Microbiome Study

Lead Product(s): Live bacterial therapeutics,Nivolumab,Ipilimumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Cancer Research UK

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 09, 2020

Details:

The collaboration is based on clinical studies conducted by CUH that evaluate immune checkpoint inhibitor drug response in cancer patients, combined with Microbiotica’s unrivalled microbiome profiling and analysis capability.

Amphista Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Amphista Therapeutics Appoints Leading Protein Degradation Pioneer, Ian Churcher as CSO

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 21, 2020

Details:

Amphista believes that Ian Churcher's scientific leadership will be a tremendous addition to the Amphista team as it progresses its TPD pipeline to the clinic.

Valo Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology

Lead Product(s): Antigen peptides,ONCOS-102 adenovirus

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Peptide

Partner/Sponsor/Collaborator: Targovax

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 22, 2020

Details:

With this collaboration, the parties will test whether PeptiCRAd coating of ONCOS-102 adenovirus with TG mutant RAS peptides can generate enhanced CD4+ and CD8+ T-cell responses against mutant RAS.

Amphista Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Amphista Therapeutics Raises $7.5m Series A Round to Advance Targeted Protein Degradation Assets in Cancer

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Advent Life Sciences

Deal Size: $7.5 million Upfront Cash: Undisclosed

Deal Type: Series A Financing April 07, 2020

Details:

This international financing provides Amphista with a firm foundation to underpin a Series B round to progress its oncology pipeline to the clinic.

Cancer Research

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Ideaya Biosciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration March 11, 2020

Details:

The expanded research collaboration will evaluate IDEAYA's PARG inhibitors in vitro in multiple ovarian cancer cell lines and in vivo in ovarian cancer xenograft models.

Immunocore

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Innovent and Sirnaomics Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Sintilimab and RNAi in the US

Lead Product(s): Sintilimab,Cotsiranib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 06, 2020

Details:

The firms have entered into a mutual partnership to perform clinical studies using Sirnaomics' RNAi drug candidate STP705 and Tyvyt by Innovent and , for combination treatment in advanced cancers.

Find

Find Novel Oncology Drugs in Clinical Development in UNITED KINGDOM

United Kingdom

Product Type

Companies

Tiziana Life Sciences

Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody

Microbiotica

Microbiotica, Cancer Research UK and Cambridge University Hospitals Collaborate in Landmark Cancer Microbiome Study

Amphista Therapeutics

Amphista Therapeutics Appoints Leading Protein Degradation Pioneer, Ian Churcher as CSO

Valo Therapeutics

Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology

Amphista Therapeutics

Amphista Therapeutics Raises $7.5m Series A Round to Advance Targeted Protein Degradation Assets in Cancer

Cancer Research

IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration

Immunocore

Innovent and Sirnaomics Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Sintilimab and RNAi in the US